Welcome to the sixth JAV newsletter!

‘Dear Partner,

Welcome to our last newsletter, as the project is coming to its end on the 31st of March 2022.

As for the previous ones, we want to inform you on what kept us busy, and to provide information on EU-JAV advances.

After more than three and a half years of work, the EU Joint Action on Vaccination leaves concrete tools and recommendations to strengthen cooperation in Europe in the vaccination field. We are hoping that you appreciated being with us during these years, following our different reports, surveys, reviews, and meeting, and that you will keep getting information on vaccination in the future.

Have a good week and enjoy your reading!’

Dear all,

Launched in the Summer 2018, the EU-JAV will come to an end at the end of March 2022. After more than 3 years and half (with an 8-month extension due to the burden of Covid-19), we will finally have achieved the launch of three platforms (one for the visualisation of vaccine coverage at a supranational level, one for the visualisation of the vaccination-centered conversation in the social media and more broadly online, and one for the gathering of reports of initiatives and actions conducted in Europe regarding vaccine hesitancy and uptake and their analysis); we also delivered many reports regarding various aspects of the vaccination, and how to obtain better scientific research and research funding, better anticipation of needs and procurement, better evaluation of vaccine coverage, better training of healthcare professionals, and better communication toward Youth, and how to carry out such actions at a supranational level.

In addition to these tools and to the documents describing these survey and analysis, we are preparing recommendations and policy briefs to help stakeholders, policy-makers, and political leaders to make these results their own and include them into their actions regarding the health of European populations.

Indeed, March 2022 may be the last month of the consortium, but the EU-JAV legacy will endure, thanks to the commitment of all: we aimed it will be a game-changer at the scale of the continent.

Thank you for being with us along the way; and please, consider yourself the recipient all the EU-JAV production!

Yours,

O.Epaulard

EU-JAV coordinator

To monitor and address the pre-service and in-service needs of healthcare students and professionals, two tools were elaborated and tested: a “vaccine barometer”, which allows measuring the skills and the needs of participants regarding vaccination knowledge and practice; and a complete curriculum on vaccination, which addresses all the different relevant topics in the field. Each country and each healthcare student/professional association can make its own these tools and improve the impact of these crucial agents on vaccine uptake.

Two communication actions toward Youth were implemented; they consisted of two competitions for the elaboration of posters and videos promoting HBV and HPV vaccination. These actions were successful, and were opportunities to determine how some wider, future actions should be designed and launched.

A platform to monitor and compare at national and subnational levels harmonised vaccine coverage was built upon a specific extension of the software R; with the example of measles-containing vaccines, it allows to identify immunisation gaps in spite of the complexity resulting from the difference of vaccines schedules between different countries.

A study of the existing reminder systems was performed in 17 countries. Such systems are designed to ensure that as many individuals as possible will receive the recommended vaccines. All countries have reminder systems in place but the study highlighted the heterogeneity of these systems between European countries both the nature and the extension of the systems.

A survey of the prerequisites, the operational implementation, and the perceived barriers and enablers for conducting cross-borders vaccination campaigns was performed through questionnaires and workshops with 28 European countries; it paves the way to implement such international actions focused on a cross-border area.

A study of past vaccine shortages experiences was conducted; it allows identifying the vaccines involved and the causes (often multiple) of such shortages, and to emit recommendations to prevent these episodes.

A study of financing mechanisms and of the feasibility of joint vaccine procurement (gathering EU member states) instead of national procurement was conducted, and led to a better understanding of how the ecosystem of vaccine procurement may evolve in the near future. In addition, a survey on the stockpiling of vaccines and the exchanges of vaccine stockpiles between EU member states has been conducted.

A method to consensually identify research priorities in vaccination has been elaborated, and was applied in 2020 and 2021 to set annual lists of the most relevant research topics that should receive attention and funding in the near future.

A survey regarding the mechanisms that may lead entities that provide research funds to collaborate and adopt joint funding to increase the efficiency of the research has been conducted.

A platform to gather as much as possible documents accounting for past experiences of EU member states in their efforts to address vaccine hesitancy has been launched; the many features on this platform allow to identify the best practices and the most efficient action in this field.

A platform that displays the monitoring of the vaccine confidence as expressed in the social media and the content of the online conversation regarding vaccine and vaccination has been elaborated.

March 9th, 2022

in PARIS

The European Joint Action on Vaccination (EU-JAV), co-funded by EU’s Health Program and the European Health and Digital Executive Agency (HaDEA), is pleased to inform you of its final conference.

Since 2018, teams from 20 EU/EEA countries have worked together to design, develop and propose a common approach towards a strengthened, winning fight against vaccine-preventable diseases within Europe.

The different teams that collaborated in this Joint Action presented the results of their work, the conclusions reached after thorough research and detailed scientific analysis, and their recommendations for -doable- European-wide actions against vaccine-preventable diseases.

The EU-JAV Final Conference was a hybrid event: it took place in Paris, France, and also online.

For more information visit eu-jav.com or follow EU-JAV social media accounts (@eujav @eu__jav)

On behalf of

all the partners – EU-JAV consortium, EU and non-EU Member States,

National Public Health Organization (NPHO / EODY) – Greece, and Inserm – France